News coverage about Ocata Therapeutics (NASDAQ:OCAT) has been trending positive on Thursday, Accern reports. The research group identifies positive and negative media coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Ocata Therapeutics earned a media sentiment score of 0.36 on Accern’s scale. Accern also assigned news stories about the biotechnology company an impact score of 45.0967950533712 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

Shares of Ocata Therapeutics (NASDAQ:OCAT) remained flat at $8.47 on Thursday. Ocata Therapeutics has a 52-week low of $3.06 and a 52-week high of $8.71. The stock’s 50 day moving average price is $8.42 and its 200-day moving average price is $6.15.

ILLEGAL ACTIVITY WARNING: “Positive Press Coverage Somewhat Unlikely to Impact Ocata Therapeutics (OCAT) Share Price” was published by Watch List News and is owned by of Watch List News. If you are viewing this piece on another website, it was copied illegally and republished in violation of United States and international trademark & copyright law. The original version of this piece can be accessed at

About Ocata Therapeutics

Ocata Therapeutics, Inc, formerly Advanced Cell Technology, Inc, is a biotechnology company focused on the development and commercialization of Regenerative Ophthalmology therapeutics. The Company’s advanced products are in clinical trials for the treatment of Stargardt’s macular degeneration, dry age-related macular degeneration, and myopic macular degeneration.

Insider Buying and Selling by Quarter for Ocata Therapeutics (NASDAQ:OCAT)

Receive News & Ratings for Ocata Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocata Therapeutics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.